期刊
ACTA PHARMACEUTICA SINICA B
卷 11, 期 4, 页码 941-960出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2020.12.018
关键词
Inflammatory diseases; Cancer immunotherapy; Atherosclerosis; Pulmonary artery hypertension; Biologics; Adoptive cell transfer; Immune targets; Drug delivery
资金
- National Natural Science Foundation of China [81872823, 82073782]
- Double FirstClass (China) of the China Pharmaceutical University [CPU2018PZQ13]
- Shanghai Science and Technology Committee (China) [19430741500]
- Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine (China) [TCM-201905]
- City University of Hong Kong (China) [9610472]
The onset and progression of inflammatory diseases such as cancer, vascular inflammation, and autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy plays a critical role in combating these diseases, while drug delivery strategies are potent in promoting their delivery.
The initiation and development of major inflammatory diseases, i.e., cancer, vascular inflammation, and some autoimmune diseases are closely linked to the immune system. Biologics-based immunotherapy is exerting a critical role against these diseases, whereas the usage of the immunomodulators is always limited by various factors such as susceptibility to digestion by enzymes in vivo, poor penetration across biological barriers, and rapid clearance by the reticuloendothelial system. Drug delivery strategies are potent to promote their delivery. Herein, we reviewed the potential targets for immunotherapy against the major inflammatory diseases, discussed the biologics and drug delivery systems involved in the immunotherapy, particularly highlighted the approved therapy tactics, and finally offer perspectives in this field. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据